Health Canada Approves New Use for Mounjaro to Lower Heart Risk in Type 2 Diabetes Patients
Published
Health Canada has approved a new use for Mounjaro, a medicine with the active ingredient tirzepatide. The approval means the drug can now be used to lower the risk of major adverse cardiovascular events, or MACE, in adults with type 2 diabetes. MACE includes serious heart-related problems such as heart attack, stroke, and death from heart causes.
Mounjaro is already used in Canada to help adults with type 2 diabetes control their blood sugar levels. The new approval adds a second purpose for the medicine. Doctors can now consider it for patients who have type 2 diabetes and are at higher risk of heart and blood vessel problems. The drug is given as a once-weekly injection.
Health Canada is the federal agency that reviews and approves medicines for use in Canada. Before approving a new use, the agency checks clinical trial results to confirm that a drug is safe and effective for that purpose. Patients who have questions about whether this treatment is right for them should speak with their doctor or pharmacist.
Type 2 diabetes is a common condition in Canada, and heart disease is one of the most serious complications for people who have it. The new approval gives patients and doctors another option for reducing that risk, alongside lifestyle changes and other treatments.
Sources: Benefits and Pensions Monitor
More Canada news
- Deloitte Canada Expands Blue J Deal to Bring Proprietary Knowledge and MCP Integration to Legal Work
- GTA VI Is Here: Where Canadians Can Buy It and Which Consoles Can Run It
- AI Company Anthropic Seeks Gas Lead for Canada with Salary Up to $500,000
- Canadian Startups Warned About Relying on a Single AI Provider
- Bloc Québécois Leader Presents Views on New Environment and Climate Bill
- Newfoundland and Labrador Gives $1.25 Million to Community Food Sharing Association
- Ottawa Plans Study to Strengthen Divorce Act and Address Family Violence
- Canada and U.S. Officials Hold Advisory Committee Meeting for the First Time Since Midterm Elections